title: Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis.
abstract: Oral mucositis is a major cause of morbidity in high-dose therapy/autologous stem cell transplantation (HDT/ASCT), where microbial colonization has an important pathological implication. In this study, we evaluated the impact of miconazole mucoadhesive buccal tablet (MBT) on mucositis-related complications. During two consecutive 34-month periods, patients treated with HDT/ASCT in our hematology department received either miconazole MBT (60 patients) or conventional oral amphotericin B suspensions three times a day (44 patients) in order to prevent or decrease chemotherapy-induced mucositis. The use of miconazole MBT is associated with less infectious complications as indicated by shorter antibiotic use (7.8 vs. 12.3 days; p < 0.0001), shorter intravenous antifungal use (1.4 vs. 3.6 days; p = 0.02), and a trend towards less yeast contamination in stool samples. Less patients required any analgesic drugs during hospitalization in the miconazole MBT group (18 vs. 7 %; p = 0.09). Indirect indicators of chemotherapy-induced mucositis (duration of hospitalization, morphine use) were in favor of miconazole MBT in patients with multiple myeloma (MM) but not for those with lymphoma. This study suggests that miconazole MBT provides a valid alternative to oral amphotericin B suspensions in regards to mucositis-related complications. A prospective and randomized study is warranted to establish the definite role of miconazole MBT.
authors.affiliation: Service des Maladies du Sang, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.
authors.forename: C
authors.initials: C
authors.lastname: Orvain
authors.forename: M P
authors.initials: MP
authors.lastname: Moles-Moreau
authors.forename: S
authors.initials: S
authors.lastname: François
authors.forename: M
authors.initials: M
authors.lastname: Mercier
authors.forename: F
authors.initials: F
authors.lastname: Moal
authors.forename: J F
authors.initials: JF
authors.lastname: Hamel
authors.forename: E
authors.initials: E
authors.lastname: Parot-Schinkel
authors.forename: N
authors.initials: N
authors.lastname: Ifrah
authors.forename: M
authors.initials: M
authors.lastname: Hunault-Berger
authors.forename: A
authors.initials: A
authors.lastname: Tanguy-Schmidt
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D060828:Induction Chemotherapy; D008297:Male; D008825:Miconazole / Q000627:therapeutic use*; D008875:Middle Aged; D052016:Mucositis / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D009101:Multiple Myeloma / Q000188:drug therapy; D011446:Prospective Studies; D013280:Stomatitis / Q000188:drug therapy / Q000517:prevention & control*; D013607:Tablets; D014182:Transplantation, Autologous / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D013607:Tablets; D008825:Miconazole; D000666:Amphotericin B
references.citation: Biol Blood Marrow Transplant. 2014 Jul;20(7):1026-32
references.pmid: 24699116
references.citation: Bone Marrow Transplant. 2002 Nov;30(9):587-91
references.pmid: 12407433
references.citation: Bone Marrow Transplant. 2011 May;46(5):727-32
references.pmid: 20818449
references.citation: Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238
references.pmid: 19747629
references.citation: Cancer. 2008 Jan 1;112(1):204-11
references.pmid: 18044772
references.citation: Neoplasia. 2004 Sep-Oct;6(5):423-31
references.pmid: 15548350
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2201-5
references.pmid: 11304772
references.citation: Cochrane Database Syst Rev. 2011 Apr 13;(4):CD000978
references.pmid: 21491378
references.citation: Biol Blood Marrow Transplant. 2010 May;16(5):678-85
references.pmid: 20045479
references.citation: Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):186-91
references.pmid: 20511163
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5471-89
references.pmid: 17909198
references.citation: Mycoses. 2010 Sep;53(5):434-7
references.pmid: 19531099
references.citation: Support Care Cancer. 2013 Nov;21(11):3191-207
references.pmid: 23832272
references.citation: Oral Oncol. 2002 Jun;38(4):337-42
references.pmid: 12076696
references.citation: Clin Infect Dis. 2012 May;54(10):1480-4
references.pmid: 22495075
references.citation: Br J Haematol. 2006 Nov;135(3):374-81
references.pmid: 16995885
references.citation: Bone Marrow Transplant. 2003 Jan;31(1):51-5
references.pmid: 12621507
references.citation: Bone Marrow Transplant. 2009 Jan;43(2):141-7
references.pmid: 18776926
references.citation: Cancer. 2004 May 1;100(9 Suppl):1995-2025
references.pmid: 15108222
references.citation: Br J Clin Pharmacol. 2004 Oct;58(4):345-51
references.pmid: 15373926
references.citation: Bone Marrow Transplant. 2006 Oct;38(7):501-6
references.pmid: 16980998